Lucid Diagnostics Inc. (NASDAQ: LUCD) is a Healthcare company (Medical - Devices) with a market capitalization of $76M. The Maz Rating grades it against the other companies in its sector.
About three months ago (July 2, 2026), Lucid Diagnostics Inc. had a Maz Rating of 1.85 out of 5 (D, Sell), ranked against the other companies in its sector. Its strongest factor then was Growth (4.60), among the strongest in its sector; its weakest was Profitability (1.08), among the weakest in its sector. The other factors: Valuation 2.85 (valued in line with its sector); Momentum 2.77 (around the middle of its sector); Financial Health 1.11 (among the weakest in its sector). The current rating is for members: log in to see it.
At $0.40, Lucid Diagnostics Inc. trades at 13.4x sales and 6.4x book value. Over the last twelve months it generated about $6M of revenue and a net loss of $93M. It runs a gross margin of -25.8%, an operating margin of -930.9% and a net margin of -959.8%. It shows return on equity of -404.3%, return on invested capital of -141.4% and a free cash flow yield of -64.8%. On the balance sheet: a debt-to-equity ratio of 2.28 and a current ratio of 1.33. Over the past 52 weeks the share price ranged from $0.30 to $1.63, with a beta of 1.16.
Lucid Diagnostics Inc. does not currently pay a dividend.
6 Wall Street analyst ratings cover the stock: 6 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.